Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05600140
Other study ID # NL81584.091.22
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 6, 2024
Est. completion date September 2026

Study information

Verified date April 2024
Source Royal Dutch Visio
Contact Bianca Huurneman, PhD
Phone 0(031)646944002
Email biancahuurneman@visio.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Viewing strategies are strategies used to process visual Information. Many children with visual impairment seem to lack systematic viewing strategies. However, it is unknown how viewing strategies differ between children with normal vision and children with (cerebral) visual impairment. In addition, viewing strategy training is often adopted in clinical practice, but till date there is no scientific evidence about effectiveness of this approach. The current project has two goals: (1) to measure viewing strategies used by children with normal vision, children with ocular visual impairment and children with CVI, and (2) to evaluate whether training viewing strategies results in more efficiënt visual Information processing.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date September 2026
Est. primary completion date June 2026
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 5 Years to 12 Years
Eligibility Inclusion criteria typically developing children with normal vision: - Age 5-12 years - linear distant visual acuity of 0.1 logMAR or better - Verbal IQ above 70 - Absence of developmental disorders or psychiatric problems like ASS or AD(H)D Inclusion criteria for children with ocular visual impairment: - Age 5-12 years - Children with linear distance visual acuity better <=1.3logMAR and >0.1 logMAR - Intact central visual field (at least > 30 degrees) - Children with a verbal IQ above 70 - Absence of developmental disorders or psychiatric problems like ASS or AD(H)D Inclusion criteria for children with cerebral visual impairment: - Age 5-12 years - Linear distance visual acuity <=0.3 logMAR - Having the diagnosis CVI (verified by ophthalmologists) - Children with a verbal IQ above 70 - Absence of psychiatric problems like ASS or AD(H)D Additional inclusion criterion for study 2 (evaluating training effectiveness): children with (cerebral) visual impairment should have an indication for viewing strategy training. Training should not be indicated if children have no problems performing academic tasks (i.e. when speed and accuracy of visual processing is within the normal range). The age range for study 2 is 5-9 years. Exclusion criteria: - Children with VI: linear near visual acuity >1.0 logMAR - Children with visual field defect < 30 degrees - Children with a verbal IQ below 70 - Children who attended a form of vision training in the past two years - Children with psychiatric problems like ASS or AD(H)D - Auditory impairment or language impairments - Major life events during training

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Viewing strategy training
Children receive a visual training of viewing strategies (six weeks, 2 times a week, 30 minutes). During the training, children are instructed to use specific viewing strategies (looking in a structured direction which fits the task at hand, zooming in and out / change of visual selective attentional field, visual discrimination). The verbal instructions and exercises are protocol-based. A textbook is used to describe the reactions of the children during training.

Locations

Country Name City State
Netherlands Royal Dutch Visio Nijmegen

Sponsors (2)

Lead Sponsor Collaborator
Royal Dutch Visio Radboud University, Behavioural Science Institute, Nijmegen, The Netherlands

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in reading accuracy after viewing strategy training Radner reading test Group A: Day 0, Month 2, Month 8; group B: Day 0, Month 2, Month 4
Primary Changes in reading speed after viewing strategy training Radner reading test Group A: Day 0, Month 2, Month 8; group B: Day 0, Month 2, Month 4
Primary Changes in visual search accuracy after training Accuracy during conjunction search Group A: Day 0, Month 2, Month 8; group B: Day 0, Month 2, Month 4
Primary Changes in visual search speed after training Speed during conjunction search Group A: Day 0, Month 2, Month 8; Group B: Day 0, Month 2, Month 4
Primary Changes in saccade amplitudes during reading and visual search after training Saccade amplitudes measured using Radner reading test and conjunction search Group A: Day 0, Month 2, Month 8; Group B: Day 0, Month 2, Month 4
Primary Changes in fixation duration during reading and search after training Fixation durations measured using Radner reading test and conjunction search Group A: Day 0, Month 2, Month 8; Group B: Day 0, Month 2, Month 4
Primary Changes in average distance between fixation points during conjunction search (EB-VSA) after training Average distance between fixation points using Radner reading test and conjunction search Group A: Day 0, Month 2, Month 8; Group B: Day 0, Month 2, Month 4
Secondary Changes in WISC-V visual processing speed index (VSI) after training WISC-IV visual processing speed index Group A: Day 0, Month 2, Month 8; Group B: Day 0, Month 2, Month 4
Secondary Changes in local visual selective attention after training TEA-Ch Speurtocht (total number of symbols found in 1 minute) Group A: Day 0, Month 2, Month 8; Group B: Day 0, Month 2, Month 4
Secondary Changes in global visual selective attention after training Gestalt Closure (Kaufman-ABC), number of correct answers Group A: Day 0, Month 2, Month 8; Group B: Day 0, Month 2, Month 4
Secondary Changes in visual identification speed after training 'DST-Plaatjes Benoemen', number of pictures correctly named within 1 minute Group A: Day 0, Month 2, Month 8; Group B: Day 0, Month 2, Month 4
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03872479 - Single Ascending Dose Study in Participants With LCA10 Phase 1/Phase 2
Active, not recruiting NCT02595502 - Clinical Evaluation of Two Silicone Hydrogel Daily Disposable Contact Lenses N/A
Completed NCT02485054 - A Predictive Score for the Ischemic Etiology of a Transient Visual Disturbances (VASCO)
Completed NCT00985231 - Performance Evaluation of Contact Lenses Among a Population of Adapted Contact Lens Wearers N/A
Recruiting NCT05208658 - Characteristics of the Vergence Responses of Binocularly Normal Subjects After a Vision Therapy Protocol N/A
Recruiting NCT06077682 - Cycloplegic Refraction in Pediatric Patients With Esotropia Phase 4
Active, not recruiting NCT04123626 - A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene Phase 1/Phase 2
Recruiting NCT04693247 - Handheld Device Compared With a Standard Eye Care Diagnostic Device in Measuring Ophthalmic Refraction N/A
Completed NCT01318577 - Study of A New Contact Lens Cleaning and Disinfecting Solution N/A
Completed NCT03763721 - The ADVISE Study: Advanced Visualization In Corneal Surgery Evaluation N/A
Completed NCT05602402 - To Evaluate the Efficacy and Safety of CAEP-01 on Eye Strain in Children With Heavy Screen Use N/A
Not yet recruiting NCT06085430 - Kubota Glass Parameter Refinement Study N/A
Completed NCT04347564 - Usability of the Software MacuFix for the Categorization of Metamorphopsia
Completed NCT01698788 - Effect of Intraoperative Dexamethasone Implant in Taut Posterior Hyaloid Removal in Diabetic Macular Edema N/A
Completed NCT01546402 - Intraoperative Dexamethasone Implant Improves Outcome of Cataract Surgery With Diabetic Macular Edema Phase 4
Completed NCT03169855 - Validation of Mesopic and Photopic Contrast Vision Tests With Respect to Nighttime Driving Ability
Terminated NCT03913130 - Extension Study to Study PQ-110-001 (NCT03140969) Phase 1/Phase 2
Recruiting NCT03479021 - SPOT Vision Screening
Completed NCT03780257 - Study to Evaluate Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene Phase 1/Phase 2
Recruiting NCT04855045 - An Open-label, Dose Escalation and Double-masked, Randomized, Controlled Trial Evaluating Safety and Tolerability of Sepofarsen in Children (<8 Years of Age) With LCA10 Caused by Mutations in the CEP290 Gene. Phase 2/Phase 3